Sign In
Buy LRMR
$3.20
-0.1000 (-3.03%)
At Close: Jun 03, 2026
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
07:00am, Thursday, 14'th May 2026
Intending to initiate rolling BLA seeking accelerated approval with submission of nonclinical and clinical modules in June 2026; submission of the final modules including the CMC module expected in se
BALA CYNWYD, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disea
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of “Buy” by Brokerages
02:22am, Monday, 27'th Apr 2026
Shares of Larimar Therapeutics, Inc. (NASDAQ: LRMR - Get Free Report) have been assigned a consensus recommendation of "Buy" from the ten ratings firms that are presently covering the company, MarketB
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
07:00am, Thursday, 19'th Mar 2026
* Pro forma cash, cash equivalents, and marketable securities of $244.5 million reflects $136.9 million of cash, cash equivalents and marketable securities as of December 31, 2025 combined with the $1
Investors Buy Large Volume of Larimar Therapeutics Call Options (NASDAQ:LRMR)
02:06am, Sunday, 15'th Mar 2026
Larimar Therapeutics, Inc. (NASDAQ: LRMR - Get Free Report) was the target of some unusual options trading activity on Friday. Investors purchased 3,011 call options on the company. This represents an
2 Breakout Stocks to Buy Immediately
12:00pm, Sunday, 08'th Mar 2026
Tom Yeung here with your Sunday Digest . In 2015, I visited the observatory at One World Trade Center – the newly opened viewing deck on the Western Hemisphere's tallest building.
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?
11:30am, Friday, 06'th Mar 2026
Larimar's stock jumps 55% in a month after the FDA grants breakthrough therapy status to its FA drug nomlabofusp and backs a potential accelerated path.
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
04:05pm, Wednesday, 04'th Mar 2026
BALA CYNWYD, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disea
Market Today: Stocks Slide, Oil Majors Rally, Big Deals and FDA Setbacks
05:34pm, Tuesday, 03'rd Mar 2026
Guru Stock PicksKen Fisher has made the following transactions:Reduce in DEO by 23.8%Sold out in VSHAdd in AMKR by 204.55%New position in BROChuck Royce has mad
First Look: Iran Shock Roils Markets; Target Beats, Amazon Buys
07:38am, Tuesday, 03'rd Mar 2026
Stock News Hormuz disruption risks energy shock: Exxon Mobil (XOM) and global markets face rising supply risks as Iran claims to have shut the Strait of Hormuz;
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
08:59pm, Wednesday, 25'th Feb 2026
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
04:01pm, Wednesday, 25'th Feb 2026
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare
Laminar Therapeutics Stock Is Popping Today: What's Going On?
02:30pm, Wednesday, 25'th Feb 2026
Larimar Therapeutics Inc (NASDAQ: LRMR) shares are jumping on Wednesday after multiple analysts reiterated their bullish outlook.
Larimar Therapeutics (LRMR) Surges On FDA Breakthrough Therapy Designation
12:12pm, Tuesday, 24'th Feb 2026
The designation covers adults and children with the rare disease and was based on data from an ongoing open-label study. Here's what investors need to know.
Nomlabofusp program granted Breakthrough Therapy Designation for the treatment of adults and children with FA based on FDA's review of available clinical data from open label study FDA written communi
